Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
RootPath Genomics
RootPath is a biotechnology company that builds powerful personalized T cell therapy platform.
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Company
Organization
B2X
B2B
CEO
Xi Chen
0
Legal Name
RootPath Genomics, Inc.
Company Operating Status
Active
Country
China
0
United States
0
Crunchbase URL
crunchbase.com/organiz...rootpath
Email Address
info@rootpath.com
0
Founder
Le Cong
Xi Chen
0
Yinquing Li
Cheryl Cui
Ely Porter
0
Full Address
325 Vassar St Ste 2A Cambridge, MA, 02139-4818 United States
Kejiyuan Rd, No 20 Building #13 HANGZHOU, Zhejiang China 310018
0
B1-1604 Yunsheng Science Park 11 Mid Guangpu Road GUANGZHOU, Guangdong China 510633
0
RootPath 65 Grove Street Suite 203 Watertown, MA 02472
0
Headquarters
Watertown, Massachusetts
0
Industry
T cell
Cancer
Cell therapy
Genomics
Biomedical engineering
Biopharmaceutical
Technology
Biology
Biotechnology
Internal medicine
•••
Investors
Sequoia Capital
Baidu Ventures
Nest.Bio Ventures
Volcanics Ventures
Oriza Seed Venture Capital
Matrix Partners China
Sequoia Capital China
Latest Funding Round Date
January 2020
Latest Funding Type
Series A
Legal classification
Corporation
LinkedIn URL
@company/rootpath-genomics/about
Location
Hangzhou
0
Guangzhou
0
United States
Watertown, Massachusetts
0
Cambridge, Massachusetts
Number of Employees (Ranges)
1 – 10
Patents Assigned (Count)
1
Total Funding Amount (USD)
18,000,000
Official Website
rootpath.com
Find more companies like RootPath Genomics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE